MiNK Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Established
- 2017-01-01
- Employees
- 31
- Market Cap
- $32.4M
- Introduction
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 34
- Registration Number
- NCT05108623
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
๐บ๐ธNorton Cancer Health, Louisville, Kentucky, United States
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04754100
- Locations
- ๐บ๐ธ
Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida, Louisville, Kentucky, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธUniversity of Cincinnati Cancer Center, Cincinnati, Ohio, United States
Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- MiNK Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04582201
- Locations
- ๐บ๐ธ
Saint John's Cancer Institute, Santa Monica, California, United States
๐บ๐ธNorton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
๐บ๐ธWeill Cornell Medicine New York Presbyterian, New York, New York, United States